Relmada Therapeutics Q2 2024 GAAP EPS $(0.59) Beats $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics (NASDAQ:RLMD) reported a Q2 2024 GAAP EPS of $(0.59), beating the analyst consensus estimate of $(0.81) by 27.16%.
August 07, 2024 | 8:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics reported a Q2 2024 GAAP EPS of $(0.59), which is better than the analyst consensus estimate of $(0.81). This positive earnings surprise could boost investor confidence in the short term.
The better-than-expected earnings report indicates that the company is performing better than analysts had anticipated, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100